What is the brand name of Entrectinib?

Entrectinib (Entrectinib) is a multi-target targeted drug, which has different trade names in different regions. In the Chinese market, the drug was introduced and launched by Roche under the trade name "Luo Shengquan". This name has been familiar to more and more patients and has gradually entered the mainstream drug list of targeted tumor therapy. In overseas markets, especially in the United States and Europe, entrectinib is sold and promoted under the trade name "Rozlytrek" and was approved by the FDA as early as 2019.

For patients, knowing the trade names of drugs can help them find reliable medication channels in different countries and regions. Especially when purchasing drugs across borders or querying overseas clinical data, using the name "Rozlytrek" will make it easier to obtain authoritative information. In China, "Luo Shengquan" is uniformly used in hospital prescriptions or medical insurance reimbursement. This also reflects the common situation in international drug registration, that is, the same drug will adopt different brand names based on marketing strategies and language habits.

It should be noted that although the names are different, they are essentially the same drug with exactly the same ingredients, and there are no differences in indications, usage and dosage. Some patients may encounter different versions of promotional or sales information on the Internet. As long as they confirm the English name "Entrectinib", whether it is Luo Shengquan or Rozlytrek, they can safely understand it as the same drug.

Currently, Luo Shengquan has been approved in China for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors, which is consistent with Rozlytrek’s indications in Europe and the United States. This means that domestic patients can enjoy internationally synchronized innovative treatments without having to rely on overseas drug purchases.

To summarize, the trade name of entrectinib in China is Luo Shengquan, and the trade name overseas is Rozlytrek. There is no substantial difference between the two. When choosing drug channels, patients should pay more attention to the approval number and formal source of the drug, rather than the simple name difference, so as to ensure the safety and effectiveness of the drug.

Reference materials:https://www.roche.com/products/rozlytrek